Cognitive and Inflammation Targeted Gut-Brain Interventions in People Living with HIV who are High-Risk Alcohol Users

Information

  • Research Project
  • 10304326
  • ApplicationId
    10304326
  • Core Project Number
    P01AA029543
  • Full Project Number
    1P01AA029543-01
  • Serial Number
    029543
  • FOA Number
    RFA-AA-20-009
  • Sub Project Id
    9214
  • Project Start Date
    9/10/2021 - 2 years ago
  • Project End Date
    8/31/2026 - 2 years from now
  • Program Officer Name
  • Budget Start Date
    7/1/2021 - 2 years ago
  • Budget End Date
    6/30/2022 - a year ago
  • Fiscal Year
    2021
  • Support Year
    01
  • Suffix
  • Award Notice Date
    9/9/2021 - 2 years ago
Organizations

Cognitive and Inflammation Targeted Gut-Brain Interventions in People Living with HIV who are High-Risk Alcohol Users

RC2 Summary The overarching goal of Research Component 2 (RC2) is to determine whether two non-invasive biological interventions, transcutaneous vagal nerve stimulation (tVNS) and a probiotic supplementation intervention (PBI), will improve cognitive and brain functioning, systemic and neuroinflammation, and gut microbiome health in people living with HIV (PWLH) who are high risk users of alcohol. The study will also delineate mechanisms of the gut-brain axis, which is particularly relevant, given that the factors underlying adverse cognitive and brain effects of alcohol use among PLWH remains unresolved. There is also considerable public health significance if beneficial effects of tVNS and/or PBI can be demonstrated, as cognitive disturbances that adversely impact health outcomes, functional abilities and quality of life are common (~ 50% prevalence), despite marked reductions in mortality in the era of antiretroviral therapies (ART). Among PLWH with reconstituted immune function and undetectable viral loads, comorbid conditions remain common and can have adverse functional consequences. High risk alcohol use, prevalent among PLWH, not only contributes to cognitive and brain dysfunction, but also further exacerbates comorbidities (e.g. liver disease, hepatitis coinfection, obesity, and cardiovascular and gastrointestinal dysfunction), and reduces treatment adherence while increasing the propensity for high risk sexual behaviors, worse health outcomes, and transmission of the virus. The study?s clinical significance is strong given the need for effective interventions to improve cognition and health outcomes in PLWH. To test these hypotheses, we will conduct a hybrid randomized clinical trial that will enroll 80 PLWH who are high risk drinkers from our existing research infrastructure supported by the Southern HIV Alcohol Research Consortium (SHARC). In a 2x2 factorial design, participants will be randomly assigned to one of 4 conditions (tVNS+placebo, sham- stimulaiton+placebo, tVNS+probiotic, sham-stimulation+probiotic). We will obtain data on alcohol consumption, cognitive assessments, blood biomarkers, stool microbiome, and neuroimaging at three timepoints (baseline, 30-days, 90 days).

IC Name
NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM
  • Activity
    P01
  • Administering IC
    AA
  • Application Type
    1
  • Direct Cost Amount
    328946
  • Indirect Cost Amount
    74024
  • Total Cost
  • Sub Project Total Cost
    402970
  • ARRA Funded
    False
  • CFDA Code
  • Ed Inst. Type
  • Funding ICs
    NIAAA:402970\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZAA1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    UNIVERSITY OF FLORIDA
  • Organization Department
  • Organization DUNS
    969663814
  • Organization City
    GAINESVILLE
  • Organization State
    FL
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    326115500
  • Organization District
    UNITED STATES